A Multicenter, Double Blinded, Randomized, Parallel Assignment Study to Demonstrate the Efficacy of DA9601
A Multicenter, Double Blinded, Randomized, Parallel Assignment Study to Demonstrate the Efficacy of DA9601
This is a phase IV clinical study to evaluate the preventive effectiveness of
 NSAID-Associated Gastroduodenal Injury. The study is consisted of multi-center, doubleblind,
 active-controlled, stratified randomized, parallel group. A tablet of DA9601, Cytotec (200ug
 of Misoprostol), Acrofen (100mg of Aceclofenac) will be assigned randomly to the subjects for
 four weeks.
After filling an Informed consent form, subjects are joined the clinical trials. First of
 all, Screening test including the endoscopy test is performed.

 Subjects, which fit the inclusion/Exclusion criteria, are assigned randomly. Subjects takes
 investigation products as randomized.
Inclusion Criteria:

 -  Need to take NSAID pills for longer than four weeks

 -  should be normal diagnosed by the endoscopy test

 Exclusion Criteria:

 -  The patients have gastric ulcer or duodenal ulcer within 30 days

 -  The patients have a gastro-intestinal surgery within a year

 -  The patients are taking the following drugs within seven days: H2 receptor antagonist,
 PPI, sucralfate, misoprostol, Stillen etc)